PacBio Agrees To Pay $800M For Omniome To Add Complementary Short-Read Sequencing Platform

Pacific Biosciences has agreed to pay $600m upfront in cash and stock and up $200m in additional milestone payments to acquire Omniome. PacBio also announced a new private placement of common stock to raise $300m.

Klaus Ohlenschlaeger/Alamy Stock Photo
• Source: Alamy (Klaus Ohlenschlaeger / Alamy Sto/Alamy Stock Photo)

Pacific Biosciences (PacBio) has agreed to pay up to $800m to acquire Omniome, a privately held San Diego-based developer of proprietary short-read DNA sequencing technology that will complement PacBio’s long-read DNA sequencing capabilities.

“By combining with Omniome, PacBio will address both the fastest-growing and the largest sequencing applications,” PacBio CEO Christian Henry said during a conference call on 20 July

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business